CCCarl Cosgrave

Carl Cosgrave

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carl Cosgrave has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Kava Herb‐Induced Liver Injury as Verified by the Updated RUCAM

    by Sahan Withanage, Carl Cosgrave, Shoa Zafir, Eliza Flanagan, Phillip Te, Samuel Hall

    A temporal relationship between liver enzyme derangement and an herbal remedy warrants further assessment for herb‐induced liver injury (HILI). Here, we describe the use of kava, a drink traditionally consumed in Pacific Island cultures, causing acute ALT and AST elevation as assessed by an updated RUCAM score of 7. The increasing use of kava in Western society should prompt clinicians to be more aware of this rare cause of HILI. A 46‐year‐old man was referred to the emergency department with a 3‐week history of fatigue, right upper quadrant pain, and profound transaminitis. He commenced kava 10 g daily 5 weeks prior to aid sleep, which was ceased 2 weeks prior due to his biochemical derangement. Blood tests revealed an ALT of 1546 U/L and an AST of 920 U/L. An autoimmune screen, viral serology, and liver ultrasound showed no abnormalities. A liver biopsy revealed foci of hepatocellular necrosis with scattered ballooning degeneration and apoptotic bodies in the parenchyma, but normal underlying hepatic parenchyma without steatosis. Following cessation of kava, the liver enzymes improved without any other intervention. He was monitored as an outpatient and had no recurrence. The incidence of kava HILI may increase with its marketing; its exact mechanism is unknown. Ultimately, further research is needed to identify the pathogenesis of kava HILI. HILI is a significant cause of transaminitis, and clinicians should remain vigilant in patients presenting with nonspecific symptoms and a negative liver screen.


  • Rectal 5-aminosalicylic acid induced pancreatitis in a patient with newly diagnosed ulcerative colitis

    by Carl Cosgrave, Irene Lu, Jack Shembrey, Neel Heerasing

    Oral 5-aminosalicylic acid (5-ASA) are well recognised to have the potential to cause drug-induced acute pancreatitis; however, there have only been infrequent case reports of rectal formulations causing acute pancreatitis. We describe a case of rectal Mesalazine (a 5-ASA) induced acute pancreatitis. The patient was commenced on rectal 5-ASA therapy 8 weeks prior to presentation following a diagnosis of Montreal classification E1 Ulcerative Colitis on colonoscopy. After the diagnosis of acute pancreatitis was confirmed, 5-ASA was ceased and the patient made a clinical full recovery at 2 month follow-up. Despite its reduced systemic absorption, rectal 5-ASA like oral formations must be considered as a potential trigger for acute pancreatitis in patients with inflammatory bowel disease.


  • An Unexpected Case of Per-rectal Bleeding

    by Jack Shembrey, Carl Cosgrave, Neel Heerasing


  • A Curious Case of Cholestatic Liver Injury

    by Carl Cosgrave, Jack Shembrey, Damian Dowling